The Lank Center for Genitourinary Oncology and Solid Tumor Oncology at Dana-Farber Cancer Institute/Brigham & Women's Hospital, Boston, Massachusetts 02115, USA.
J Natl Compr Canc Netw. 2013 May;11(5 Suppl):653-7. doi: 10.6004/jnccn.2013.0194.
Rapid progress was recently made in the treatment of prostate cancer, especially metastatic castration-resistant prostate cancer. At the NCCN 18th Annual Conference, Dr. Philip W. Kantoff reviewed the data supporting the use of abiraterone acetate, enzalutamide, cabazitaxel, sipuleucel-T, and radium-223 (pending approval), and offered recommendations for their sequential use in different settings. Dr. James L. Mohler described factors that dictate who should receive treatment, when they should receive it, and how to treat in the setting of prostate-specific antigen elevation. He explained how better treatment decisions will result from individualized estimation of threat-to-life posed by prostate cancer, chance of cure by treatment, and treatment risks.
近年来，前列腺癌的治疗取得了快速进展，尤其是转移性去势抵抗性前列腺癌。在 NCCN 第 18 届年会上，Philip W. Kantoff 博士回顾了支持醋酸阿比特龙、恩杂鲁胺、卡巴他赛、sipuleucel-T 和镭-223（有待批准）使用的数据，并就其在不同情况下的序贯使用提出了建议。James L. Mohler 博士描述了决定谁应该接受治疗、何时接受治疗以及在前列腺特异性抗原升高的情况下如何治疗的因素。他解释了如何通过对前列腺癌对生命的威胁、治疗的治愈率和治疗风险进行个体化评估，做出更好的治疗决策。
